Curis Announces Presentation of CUDC-427 and Erivedge(R) Clinical Results at ASCO Annual Meeting
LEXINGTON, Mass., May 16, 2013 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused company seeking to develop next generation targeted drug candidates for cancer treatment, today announced that a clinical abstract reporting Phase I clinical results of CUDC-427, a small molecule antagonist of IAP proteins, has been selected for oral presentation at the 2013 Annual Meeting of the American Society of Clinical Oncology (ASCO), being held from May 31- June 4 in Chicago, IL.
Results will also be presented on two Genentech (Roche) sponsored Erivedge (vismodegib) studies, including an 18-month update of the pivotal ERIVANCE BCC clinical study, as well as an interim analysis of 300 patients in the ongoing STEVIE study. Data from both Erivedge studies will be included as part of a melanoma/skin cancers poster discussion session.
Additional information on the sessions can be found below and abstracts can be accessed at www.ASCO.org.
|
Oral Presentation Sessions: |
|
|
|
|
Date/Time: |
Sunday, June 2, 2013, 9:00 AM — 9:15 AM CT |
|
Location: |
S406 |
|
Track: |
Developmental Therapeutics - Clinical Pharmacology and Experimental Therapeutics |
|
Presentation Title: |
Phase I study of safety and pharmacokinetics (PK) of GDC-0917, an antagonist of inhibitor of apoptosis (IAP) proteins in patients (Pts) with refractory solid tumors or lymphoma. |
|
Presenter: |
Anthony Tolcher, M.D. |
|
Abstract Number: |
2503 |
|
|
|
|
Poster Discussion Sessions: |
|
|
|
|
Date/Time: |
Monday, June 3, 2013, 8:00 AM — 12:00 PM CT |
|
Location: |
S405 |
|
Presentation Title: |
Vismodegib, a Hedgehog pathway inhibitor (HPI), in advanced basal cell carcinoma (aBCC): STEVIE study interim analysis in 300 patients. |
|
Presenter: |
Jean Jacques Grob, M.D. |
|
Abstract Number: |
9036 |
|
Poster Board: |
24 |
|
|
|
|
Date/Time: |
Monday, June 3, 2013, 8:00 AM — 12:00 PM CT |
|
Location: |
S405 |
|
Presentation Title: |
Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma (aBCC): 18-month update of the pivotal ERIVANCE BCC study. |
|
Presenter: |
Aleksandar Sekulic, M.D., Ph.D. |
|
Abstract Number: |
9037 |
|
Poster Board: |
25 |
About Curis, Inc.
Curis is an oncology-focused company seeking to develop and commercialize next generation targeted drug candidates for cancer treatment. Erivedge® is the first and only FDA-approved medicine for the treatment of advanced basal cell carcinoma and is being commercialized and developed by Roche and Genentech, a member of the Roche Group, under a collaboration agreement between Curis and Genentech. Curis is also developing its pipeline of proprietary targeted cancer drug candidates, including CUDC-427, a small molecule antagonist of IAP proteins; CUDC-907, a dual PI3K and HDAC inhibitor; and CUDC-101, an EGFR/HER2 and HDAC inhibitor. For more information, visit Curis' website at www.curis.com.
CONTACT: For More Information:
Michael P. Gray
Chief Financial Officer
Curis, Inc.
617-503-6632
mgray@curis.com
